Key takeaways

  • Identify the whole product: ingredient, brand, route, strength, indication and device. The cited US Rybelsus label even distinguishes tablet formulations R1 and R2, which are not substitutes on a milligram-for-milligram basis. FDA Rybelsus label
  • Diabetes and obesity treatment have different assessment goals. A shared ingredient does not make the product instructions interchangeable. FDA Wegovy label
  • A familiar name or batch number cannot establish authenticity. FDA found counterfeit Ozempic using an authentic lot number; Australian testing found no GLP-1 or analogue in products labelled as containing them. FDA, TGA

GLP-1 medicines for diabetes and weight loss are not interchangeable

GLP-1 Medicines for Diabetes and Weight Loss Are Not Interchangeable

A semaglutide search can return Ozempic, Rybelsus and Wegovy. International labels have used Ozempic injection for type 2 diabetes, Rybelsus tablets for oral treatment, and Wegovy for chronic weight management and cardiovascular risk. Saxenda contains liraglutide for weight management in authorised populations. GLP-1 is the family: purposes, routes, strengths, devices, escalation schedules and instructions vary by product and jurisdiction. Popularity does not establish suitability or substitution.

Why do the brand names matter here?

The February 2026 US Wegovy label covers injection and tablets under one brand. Its injection weight-management indication includes certain patients aged 12 and over, while its tablet indications are for adults. The injection label also includes accelerated approval for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis in adults. These are US product examples, not evidence of current Singapore registration, availability or individual suitability. FDA Wegovy label

Rybelsus has two formulations in its cited US label. R1 tablets are oval; R2 tablets are round, both white to light yellow. The label gives separate instructions and says they cannot be substituted milligram for milligram or used together. FDA Rybelsus label

Rybelsus combines semaglutide with salcaprozate sodium, which helps its absorption, predominantly in the stomach. This is a formulated tablet with specific exposure, not simply the injectable ingredient taken by mouth. FDA Rybelsus label

Record the exact pack for the prescriber. Pen click counts, tablet instructions and escalation schedules cannot be transferred between brands. Starting and maintenance steps account for tolerability and exposure; the prescriber decides the regimen. Indications and forms can change over time and between countries.

What is different about diabetes and weight-management use?

Glucose control, other illnesses and weight-related goals shape the assessment. In type 2 diabetes, treatment selection considers glucose control, cardiovascular and kidney disease, hypoglycaemia risk, weight effects, other medicines and the person’s preferences and ability to use the formulation. In obesity care, assessment includes body-mass criteria, weight-related conditions, previous interventions, contraindications and a long-term support plan.

Someone with both conditions still needs each set of goals assessed. GLP-1 medicines are not insulin and are not used for type 1 diabetes treatment. They also should not be combined with another GLP-1 product unless a specialist plan explicitly says otherwise.

Insulin or a sulfonylurea alongside semaglutide raises the low-blood-glucose concern. Both cited US labels flag this combination for prescriber assessment. An existing history of diabetic retinopathy also calls for monitoring under those labels. FDA Rybelsus label

The single versus combination diabetes medicine guide explains how changing a component affects the wider regimen.

Why do route and instructions change the comparison?

Pens and tablets have different handling and administration requirements. Injectable products have specific devices, needles, storage and missed-dose instructions. Oral semaglutide products have unusually sensitive administration requirements related to fasting, water volume and separation from food and other oral medicines. The cited Rybelsus label specifies morning use on an empty stomach with water, then at least 30 minutes before food, drinks or other oral medicines. Tablets are swallowed whole, without splitting, crushing or chewing. These directions cannot be inferred from an injection label. FDA Rybelsus label

Nausea, vomiting, diarrhoea and constipation are common GLP-1-related adverse effects. Gradual escalation is used in product-specific regimens to improve tolerability. Persistent vomiting or diarrhoea can cause dehydration and kidney problems; severe ongoing abdominal pain requires assessment for pancreatitis or gallbladder disease.

Tell the prescriber about pregnancy plans, previous pancreatitis or gallbladder disease, severe gastrointestinal disease, kidney problems and a personal or family history relevant to the product’s thyroid-tumour contraindication. The cited US labels name medullary thyroid carcinoma and multiple endocrine neoplasia type 2 (MEN 2) in that contraindication. Their boxed warnings describe thyroid C-cell tumours in rodents and say the human relevance is unknown. Labels vary by jurisdiction and formulation. FDA Wegovy label

Why are counterfeit and compounded products a concern?

Counterfeits may have a wrong ingredient or amount, contamination or unassessed injection components. High demand has created a market for products promoted as Ozempic, semaglutide or GLP-1 alternatives. In its 5 December 2025 notice, FDA reported counterfeit Ozempic carrying PAR1229, a lot number also used by authentic product. The counterfeit’s EXP/LOT text sat to the left of the date and lot information; the authentic pen’s text was above. FDA said the six reported adverse events linked with that lot concerned authentic Ozempic and did not appear associated with the counterfeit. FDA notice

The same FDA page’s December 2023 investigation found counterfeit needles, with sterility unconfirmed, as well as counterfeit labels, cartons and patient information. Packaging photographs alone cannot establish authenticity.

Australia’s 2 March 2026 TGA alert reported no GLP-1 or analogue in the products it tested. Examples included STDEI GLP-1 Weight Loss Oral Solution and HHVB-GLP-1 Nano Microneedle Patch. These were laboratory findings about those products, not a test of all online listings. TGA alert

“Compounded” is not a synonym for generic. Compounding has a defined professional and regulatory context, and a product advertised through social media or an informal marketplace should not be assumed to come from that system. Salt forms or research-grade powders are not automatically equivalent to the active ingredient in an authorised product.

What changes the answer?

The pack details and the person’s medical history need checking together.

  • The exact product and jurisdiction. Authorised indications, route, strength and instructions can differ.
  • The treatment goal. Diabetes, obesity and cardiovascular-risk decisions use different eligibility and monitoring questions.
  • Other glucose-lowering medicines. Insulin and sulfonylureas can change hypoglycaemia planning.
  • Gastrointestinal and gallbladder history. Tolerability and serious-symptom assessment matter.
  • Pregnancy and endocrine history. Product warnings and planning require clinician review.
  • Source and storage. Brand names cannot establish whether a product is counterfeit, tampered with, overheated or improperly stored. Use the lawful, verified prescription supply route for the jurisdiction. For a suspected problem, retain the box, pen, batch information and seller record and report it to the regulator; the FDA cases show that even a familiar lot number is insufficient.

Seek urgent care for severe persistent abdominal pain, repeated vomiting with inability to maintain fluids, signs of a serious allergy, collapse or severe confusion. Contact the treating service promptly for signs of dehydration, marked reduction in urination, or significant adverse effects during escalation.

Use the diabetes-management and weight-management catalogue pages to identify ingredient families, not to convert one brand’s instructions into another’s plan.

Sources